According to the FDA, the data showed no increased risk of suicide, depression, anxiety, or related psychiatric effects compared to placebo, leading the agency to conclude that the existing warnings are not supported by the evidence
Novo Nordisk said it is working diligently to address the concerns
[28] The resistance of lipedema tissue to conventional weight loss methods has prompted investigation into pharmacological approaches
Food and Drug Administration is seeking new legislative authority to crack down on misleading direct-to-consumer drug ads, arguing it needs stronger tools to ensure companies present balanced information about risks and benefits
However, the risk increases with the addition of therapies, notably sulfonylureas and insulin, which are associated with hypoglycaemia